The High Authority for Health (HAS) and National Agency for Drug Safety (ANSM) have published a prel...
Read moreWith respects to pricing and reimbursement, the societies reportedly call for the criteria that led ...
Read moreDurvalumab was previously made available to NHS patients in 2019 through the Cancer Drugs Fund (CDF)...
Read moreSpending by the main health insurance fund (Caisse nationale d’assurance maladie, CNAM) on medicin...
Read moreEUCOPE notes that “while these proposals don’t necessarily represent the final options included ...
Read moreAccording to the report, the financing of cancer drugs in Spain is “very high” with 90% of oncol...
Read moreConsequently, paybacks from pharmaceutical manufacturers of around €1 billion will be due from pha...
Read moreThe draft final guidance reverses previous guidance issued in November 2021 rejecting the drug for r...
Read moreThe DHSC is proposing to increase the statutory scheme payment percentage for 2022 from 10.9% to 14....
Read moreThe proposals are set out in the draft Statutory Health Insurance Financial Stabilisation Bill which...
Read more